Pacific Biosciences of California, Inc. (NASDAQ: PACB) reported Q2 EPS of ($0.42), $0.20 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $10.6 million versus the consensus estimate of $4.1 million.

Earnings